Status:
NOT_YET_RECRUITING
Optimal ECMO Flow in the Critical Phase of Cardiogenic Shock to Optimize Peripheral Organ Perfusion and Myocardial Stress
Lead Sponsor:
University Hospital, Montpellier
Conditions:
Cardiogenic Shock
Eligibility:
All Genders
18+ years
Brief Summary
Veno-arterial ECMO (VA ECMO) is considered the ultimate lifesaving technique in refractory cardiogenic shock (CS). However, VA ECMO is associated with potentially serious adverse effects and complicat...
Eligibility Criteria
Inclusion
- cardiogenic shock
- treated with VA ECMO for less than 48hours
Exclusion
- ECMO initiated for refractory cardiac arrest
- Cardiac arres prior to the cardiogenic shock with Low-Flow \> 30 min
- Noradrenaline dose \> 1μg/kg/min, vasopressin dose \> 2IU/h, dobutamine dose \> 15μg/kg/min, adrenaline dose \> 1μg/kg/min, or unstabilized vasopressors or inotropes
- Post-cardiotomy cardiogenic shock
- Septic shock
- Left ventricular unloading by Impella (CP/5) or atrioseptostomy
- Atrial septal defect
- Ventricular septal defect
- Pregnant or breast-feeding women
- Patients protected by law (under guardianship or curatorship),
- Patient participating in another research study with an exclusion period still in progress
- Opposition to participation after having been informed
- Patient not affiliated to any health care system
- Patient unable to express non-opposition without available trusted person
Key Trial Info
Start Date :
April 15 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2026
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT06936839
Start Date
April 15 2025
End Date
April 1 2026
Last Update
April 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Montpellier University Hospital
Montpellier, Occitanie, France, 34090